Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fematon and SSRIs for Postmenopausal Depression with Cognitive Decline
NCT06358014Recruiting
- Start
- May 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of estradiol valerate + dydrogesterone in major depressive disorder (MDD) and cognitive impairment (2 arms). Primary endpoint: Montreal Cognitive Assessment at 8 weeks. Started May 2023; status: recruiting.
02
Drugs
estradiol valerate + dydrogesterone
03
Conditions
major depressive disorder (MDD)cognitive impairment
Beyond the preview
Go deeper on NCT06358014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06358014.